Contact Us
Drug Search Results
More Filters [+]

Betahistine

Alternative Names: betahistine
Latest Update: 2024-10-19
Latest Update Note: Clinical Trial Update

Product Description

Betahistine is a medicine used to treat the symptoms of Ménière's disease. Symptoms include: dizziness (vertigo) ringing in the ears (tinnitus) loss of hearing. (Sourced from: https://www.nhs.uk/medicines/betahistine/)

Mechanisms of Action: H3 Antagonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | Uruguay | Venezuela | Vietnam

Approved Indications: None

Known Adverse Events: None

Company: OBEcure
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Betahistine

Countries in Clinic: Spain

Active Clinical Trial Count: 2

Highest Development Phases

Phase 3: Hearing Loss|Meniere Disease|Tinnitus

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
0796-19

P3

Unknown Status

Hearing Loss|Tinnitus|Meniere Disease

2026-12-31

BERTIGO

P3

Active, not recruiting

Tinnitus|Hearing Loss|Meniere Disease

2022-10-23

Recent News Events

Date

Type

Title

09/26/2024

News Article

 Sunshine Biopharma Launches Two New Generic Prescription Drugs

09/24/2024

News Article

 Altamira Therapeutics Provides Business Update and First Half 2024 Financial Results

06/20/2024

News Article

 Altamira Therapeutics Highlights Newly Published Review Article Supporting Use of Betahistine in Vertigo Management

06/07/2024

News Article

 Public advisory - Accel-Ondansetron ODT, Mint-Betahistine and PMS-Pirfenidone tablets recalled due to data integrity concerns

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions